A life working as a consultant in the pharmaceutical industry offers substantial benefits, including flexibility and varied work. While consultants may not experience the defined career pathway we follow as an employee, we can still steer our professional journeys through mentorship, training, and networking. Read more to learn how.
PharmaMedic is delighted to announce our next virtual event on Thursday 28th October 2021 at 8 am. As the UK life sciences sector continues its journey outside the EU, it’s time to forge a new role in the international community. This briefing will highlight some of the critical considerations we face from both innovation and regulatory perspectives. Learn more about the agenda and register here.
With the government, the MHRA has launched a new consultation to shape a new era of medical device regulation in the UK. The objective is to create a framework that improves patient and public safety, increases transparency in regulatory decision-making, and aligns with global best practices. In this article, we summarise the issues and the scope of the potential changes.
In June, the government published a comprehensive report by the Taskforce on Innovation, Growth and Regulatory reform. The Prime Minister commissioned the taskforce, led by Rt Hon Sir Iain Duncan Smith MP, Rt Hon Theresa Villiers MP, and George Freeman MP, to review the UK's overall approach to regulation following Brexit. The taskforce examined the opportunities of regulatory independence in supporting cross-sector innovation. In this new article, we summarise some of the headline proposals.
Against a backdrop of achievements yielded from public/private collaborations in the context of the pandemic response, we focused our latest virtual briefing on the crucial role such partnerships play in furthering biopharma and medical devices innovation. We share highlights from the event and provide the catch-up recording in this brief summary.
PMC was delighted to feature in the latest LBIC newsletter from the London BioScience Innovation Centre discussing how the ILAP scheme is helping to secure the UK’s position as a life science superpower. Learn more.
In March 2021, the government published its document Saving and Improving lives: The Future of Clinical Research Delivery. The paper laid out an ambitious vision for a more patient-centred, pro-innovation and data-enabled clinical research environment in the UK. Following the publication of the implementation plan in June, we summarise the key themes in this article.
Join PMC for our next virtual breakfast briefing on Wednesday 21st July 2021 at 8am. Our topic for this session is “The role of public/ private collaborations to further biopharma and medical devices innovation”. We are delighted to welcome Nicki Bromwich, Chief Operating Officer of MedCity who will join Dr Malcolm Barratt-Johnson, Managing Director of PMC to discuss the ecosystem of public/ private collaboration and how it supports innovation. Read more and register.
Patient and public involvement in research is increasingly regarded as best practice. In this Q&A article, we interviewed Clinical Development Consultant Dr Joanne James to discuss her perspectives and experiences of these important initiatives, and their impact on research quality.
The MHRA's recently launched Innovative Licensing and Access Pathway scheme (ILAP) forms part of a bold vision for the UK to incentivise and support life sciences development as we emerge into a post-Brexit regulatory and clinical trials environment. PharmaMedic Consultancy is currently supporting several clients with their applications, and in this article, we share more insights about the scheme and how it stands to benefit patients and sponsors.
